Audited Financial Results ( Standalone & Consolidated) Along with Statutory Auditor''s Report
NGLFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.8 pts more than Nifty Microcap 250 and 11.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NGL Fine-Chem reported strong full-year results with consolidated revenue growing 36% to Rs 5,009.5 million (FY2025: Rs 3,682.6 million). Net profit surged 128% to Rs 481.3 million from Rs 211.2 million year-on-year, driven by robust pharmaceutical segment performance and improved operational efficiency. EBITDA margin expanded by 566 basis points to approximately 17%. The board recommended a final dividend of Rs 1.75 per share (Rs 108.12 lakhs total). Trade receivables and inventories increased significantly, reflecting business expansion. Non-current borrowings rose to Rs 564 crore from Rs 253 crore, while the company maintained positive operating cash flows of Rs 433.2 million. Statutory auditors issued an unmodified opinion with no qualifications.
The company delivered exceptional double-digit growth in both revenue and profitability with margin expansion, signaling strong execution in the pharmaceuticals business. The increase in borrowings warrants monitoring for debt servicing ability. Positive dividend declaration indicates management confidence in sustained cash generation.